Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Personalized Medicine, presented two studies at the International Spine Intervention Society’ ... 28th, 2015 through to August 1st, 2015. With a focus on evidence-based research ...
(Date:8/28/2015)... Brooklyn, NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of ... with their quirky humor and excellent customer service. Images such as the Fonz in ... website to add some flavor to the humdrum spectroscopy field. , FireflySci is ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... ) announced today that it will hold a conference call ... first quarter 2008,earnings. On Thursday, May 8, 2008 at 4:00 ... headquarters at 1450 Infinite Drive,in Louisville, CO., ... Kenneth J. Collins, President and CEO, and other members ...
... 29 Cord Blood America,Inc. (OTC Bulletin Board: ... ( http://www.cordblood-america.com ) focused on,bringing the life ... and,internationally, today reported that Matthew Schissler, CEO, in ... resulted in an 820,percent increase in assets and ...
... microscopic device that can construct nano machines have been ... International Journal of Nanomanufacturing from Inderscience Publishers, researchers describe ... 1986 book, The Engines of Creation, K Eric Drexler ... create an assembler, a microscopic device, a robot, that ...
Cached Biology Technology:Replidyne to Report First Quarter 2008 Earnings 2Replidyne to Report First Quarter 2008 Earnings 3Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined 2Are nanobots on their way? 2Are nanobots on their way? 3
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
(Date:8/4/2015)... , Aug. 04, 2015 ... http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition of ... (Hardware, Software, and Service), Sub-Segment (Computer Forensics, ... Forensics), Tool Types, Service, Vertical and Region ... to their offering. By Component ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... Stories of environmental damage and their consequences always ... country, usually a tropical one with lush rainforests and ... familiar animals are unfolding all the time in our ... from animal hosts to people when ecosystems are disrupted. ...
... State University have developed a rapid, multiplexed genotyping method ... warfarin dose. The related report by Yang et ... by SELDI-TOF Mass Spectrometry," appears in the March 2010 ... Warfarin is an anti-coagulant that is commonly used ...
... People may avoid milk and other dairy products due ... foods may not only be unnecessary to manage the ... a panel of experts assembled by the National Institutes ... Conference on Lactose Intolerance and Health was convened to ...
Cached Biology News:Emerging tick-borne disease 2Emerging tick-borne disease 3Emerging tick-borne disease 4Emerging tick-borne disease 5Emerging tick-borne disease 6Avoiding dairy due to lactose intolerance is unnecessary in most cases 2Avoiding dairy due to lactose intolerance is unnecessary in most cases 3Avoiding dairy due to lactose intolerance is unnecessary in most cases 4
... Transcriptase (M-MLV RT) is an RNA-dependent DNA polymerase ... long messenger RNA templates (>5kb). The enzyme is ... and consists of a single subunit with a ... of M-MLV RT is weaker than the commonly ...
... Collection of Cell Cultures (ECACC) in conjunction ... the West of England, Bristol, UK, have ... control of HER2, oestrogen and progresterone receptor ... sections of formalin fixed, breast cancer cell ...
... introduced the highly potent TURBO DNase (patent pending) ... was set in DNA removal capabilities. TURBO DNase ... that is much more efficient than wild type ... unwanted DNA. TURBO DNase binds DNA substrates 6-fold ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Biology Products: